According to OKYO Pharma, OK-101 is the first drug candidate to enroll patients specifically diagnosed with neuropathic ...

Glaucoma is a group of eye diseases that cause slow, progressive damage to the optic nerve in the back of the eye ... in the eye to act as a drain for the excess fluid that is putting pressure on the ...

My 60-year old Uncle was recently diagnosed with Glaucoma. Kindly let me know if the condition is curable.Silas (by ...

Age-related macular degeneration affects your central vision but leaves your peripheral vision unchanged. It's a leading ...

Cataracts, dry eyes, glaucoma, and other eye problems become more common with age. But these can be treated and even cured if ...

Injury to the eye can also cause sudden vision loss, said Dr Vinit Banga, director of neurology and head of neuro ...

OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat ...

Since mid-August, ADV Vision has successfully implanted the iDose TR in two patients, marking a new era in glaucoma treatment ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

OKYO Pharma has initiated the Phase II trial of OK-101, a treatment for neuropathic corneal pain (NCP), by dosing the first ...

To truly conquer type 2 diabetes, we must implement the lifestyle changes that studies have overwhelmingly shown to be the ...

Event: Tear Film and Ocular Surface Society (TFOS) Conference Presentation Title: Efficacy and Safety Results of First-in-Human Phase 2 Trial of OK-101 in Dry Eye Patients Presented By: Raj Patil, ...